Suiyan Fu

• PhD
• Professor at Peking University

MESSENGER magnetic field and plasma measurements taken during crossings of Mercury's magnetotail from 2011 to 2014 have been examined for evidence of substorms. A total of 26 events were found during which an Earth-like growth phase was followed by clear near-tail expansion phase signatures. During the growth phase, just as at Earth, the thinning o...

The current system associated with the boundary of plasma bubbles in the Earth's magnetotail has been studied by employing Cluster multi-point observations. We have investigated the currents in both the dipolarization front (DF, leading edge of the plasma bubble) and the trailing edge of the plasma bubble. The distribution of currents at the edge i...

Ion composition variations in the inner magnetosphere during storm times are studied by using data sets obtained from the magnetospheric ion composition spectrometer (MICS) on board the Combined Release and Radiation Effects Satellite (CRRES). The observations were made during the second half of the CRRES mission, which was near the maximum of sola...

A global view of the ring current ions is presented using data acquired by the instrument MICS onboard the CRRES satellite during solar maximum. The variations of differential intensities, energy spectra, radial profile of the energetic particles and the origin of the magnetic local time (MLT) asymmetry of the ring current have been investigated in...

3558 Background: Gene fusions are rare genomic events in colorectal cancer (CRC) and can co-occur with other potentially actionable alterations. Navigating early-phase trial selection in this scenario can be challenging. Objectives: To evaluate the genomic landscape, treatment selection, and clinical outcomes of patients (pts) with CRC harboring ge...

3072 Background: Despite breakthroughs in genomically-matched therapies, many patients lack actionable genomic alterations. Consequently, innovative new strategies to identify targets for effective therapies are imperative. To assess the potential of comprehensive whole transcriptomic sequencing (WTS) in clinical decision-making, we conducted a pro...

3086 Background: EphA2 overexpression is common in human cancers and has an important role in promoting tumor growth and metastasis. Further, EphA2 has kinase-dependent and independent functions, making it ideal for RNAi-based targeting. EphA2 siRNA incorporated in DOPC nanoliposomes (EPHARNA) was effective in reducing EphA2 protein levels and redu...

TPS2679 Background: Immunotherapies have transformed cancer treatment, yet only a small proportion of patients experiences durable responses. IVS-3001 is an innovative autologous chimeric antigen receptor (CAR) T-cell therapy specifically targeting Human Leukocyte Antigen (HLA-G). HLA-G is an immune-modulatory checkpoint molecule expressed on vario...

2660 Background: DNA repair deficiency is common among tumors, and emerging data suggest that genomic instability is associated with response to immuno-oncology (IO) therapies (PMID 28630051). We evaluated patients with advanced metastatic cancer across tumor types, who were treated on the IMPACT2 study (NCT02152254) and analyzed their clinical out...

3549 Background: Systemic therapy recommendations for young-onset colorectal cancer (YOCRC), CRC diagnosed at < 50 years old, are similar for late-onset CRC (LOCRC) despite possible differences in biologic behavior. This study aims to compare outcomes among YOCRC and LOCRC patients on Phase 1 matched and non-matched therapies. Methods: This was a s...

8635 Background: Lung cancer remains the deadliest solid tumor, with non-small cell lung cancer (NSCLC) accounting for 80–85% of cases. Patients enrolling in Phase I studies are often heavily pretreated and face limited treatment options. Understanding their demographics and therapeutic responses is crucial to improving patient outcomes. This study...

Background Transforming growth factor-beta 1 (TGFβ1) plays a crucial role in tumor progression and immunosuppression in cancer. SAR439459 is a second-generation monoclonal antibody that targets all TGFβ isoforms. A first-in-human study (NCT03192345) established the SAR439459 dose at 15 mg/kg every three weeks as the initial recommended phase 2 dose...

Background Immunotherapies have transformed cancer treatment, yet only a small proportion of patients experiences durable responses. IVS-3001 is an innovative autologous chimeric antigen receptor (CAR) T-cell therapy specifically targeting Human Leukocyte Antigen (HLA-G). HLA-G is an immune-modulatory checkpoint molecule expressed on various solid...

The concurrent use of medications can either compromise or enhance treatment (Tx) outcomes in patients with solid tumors (pts) receiving immunotherapy compounds (IO) including monoclonal antibodies (Abs), fusion proteins (FP), immune modulators (IM), oncolytic viruses (OV) and vaccines (VAC). To assess the impact of concurrent medications on Tx out...

Purpose We examined baseline diet and its association with outcomes and social determinants of health (SDoH) factors among patients (pts) enrolled in early-phase immune checkpoint blockade-included combination trials in a comprehensive cancer center. Methods Pts (ECOG 0-1) scheduled to begin an early-phase combination trial with immune checkpoint...

Background: As not all patients respond to immunotherapy, it is important to identify patients who are likely to benefit from treatment. Several factors such as hypoalbuminemia, elevated neutrophil counts, and increased LDH have been associated with poor response to immunotherapy and reduced survival outcomes. Similarly, liver metastases are associ...

Background Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. Methods NCT02419495 was a multiarm phase IB study of SEL in combin...

Introduction TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and have demonstrated efficacy in early clinical trials. This trial assessed the safety and preliminary efficacy of the combin...

Plain Language Summary Recent investigations of local dynamics near the diffusion region have revealed the crucial role of the ion‐scale flux rope in energy conversion, plasma acceleration and plasma transport during magnetic reconnection. However, it remained unclear how the flux rope is formed, especially for those with axes roughly perpendicular...

Magnetic reconnection is the key to explosive phenomena in the universe. The flux rope is crucial in three-dimensional magnetic reconnection theory and are commonly considered to be generated by secondary tearing mode instability. Here we show that the parallel electron flow moving toward the reconnection diffusion region can spontaneously form flu...

In regions of the solar system distant from planetary magnetic fields, galactic cosmic rays (GCRs) have generally been assumed to be uniformly distributed throughout interplanetary space. However, our analysis of data from the Chang’E-4 lander revealed a region of reduced GCR flux in the pre-noon sector of the lunar orbit. Further investigation sug...

Background Immune checkpoint inhibitors (ICI) revolutionized the treatment landscape of cancers. However, not all patients responded to treatment and cancer-related deaths continued to account for half of all deaths in USA in 2022.¹ With steep increase in use of immunotherapy, it is important to select patients who are likely to benefit from treatm...

Plain Language Summary The drift motion represents a typical behavior of particles within the Earth's magnetosphere. Observing particle flux during drift echo events provides us insights into magnetosphere dynamics. In our recent investigation, we discovered a rarely observed phenomenon during a relativistic electron drift echo event: the unexpecte...

Plain Language Summary In Earth's magnetosphere, electromagnetic oscillations in the mHz frequency range referred to as ultra‐low frequency (ULF) waves have been frequently reported in space and ground‐based observations. These waves have been known to interact resonantly with magnetospheric particles during their drift and bounce motions, which pl...

Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA 1/2, (2) other homologous recombination...

Objective To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments. Methods and analysis Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (...

Glioblastoma, the most common malignant brain tumor in adults, is associated with a median overall survival duration of less than 2 years. Extraneural metastases occur in less than 1% of all patients with glioblastoma. The mechanism of extraneural metastasis is unclear. We present a case of extensive extraneural, extraosseous, epidural, and soft-ti...

1635 Background: Recruitment to phase I/II clinical trials have been reported to vary between 30% and 55% across centers, primarily relying on in-person visits. However, with the onset of the COVID-19 pandemic, there has been a noticeable surge in telehealth consultations. Consequently, there is currently a dearth of data available regarding this a...

12084 Background: We examined symptom interference with activity- and mood-related functioning at baseline in early-stage trials of combination treatments that included at least one immune checkpoint inhibitor, and its association with quality of life (QOL)-, clinical-, and trial-related factors. Methods: Patients scheduled to begin an early-phase...

Background Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I trial evaluated the safety and preliminary activity of the SYK inhibitor TAK-659 combined with paclitaxel in patients with advance...

2575 Background: LVGN6051 is a 4-1BB agonistic monoclonal antibody with Fc γ-receptor IIB binding designed for selective activation in the tumor microenvironment. A prior phase Ia trial of this combination showed RP2D to be 4 mg/kg LVGN6051 with 200mg pembrolizumab. We explored the activity of this combination in resistant NSCLC, Melanoma, and GI m...

3099 Background: The MAPK pathway is frequently activated in different cancers. Inhibitors of different molecules across this pathway have been developed and approved including BRAF, MEK, and ERK inhibitors. However, limited data are available regarding response in patients with upstream RAS alterations. The interplay between RAS and downstream RAF...

3152 Background: Paclitaxel resistance in patients is a clinical challenge that limits the durability of clinical benefit in patients with taxane-responsive advanced solid tumors. One proposed mechanism for this resistance is overexpression of spleen tyrosine kinase (SYK); which can be inhibited with new molecules including TAK-659. In this phase I...

3153 Background: To address the limitations of exploratory studies, we conducted IMPACT2. The primary endpoint was to compare the progression-free survival (PFS) between patients treated with matched targeted therapies (MTT) selected on the basis of tumor molecular alterations and those whose treatment was not selected on the basis of alteration an...

TPS3182 Background: Bromodomain and extra-terminal (BET) proteins serve as epigenetic readers and regulate transcription by binding acetylated lysines in histones. BET inhibitors target this epigenetic machinery modifying the expression of oncogenes and have the potential to overcome drug resistance in different settings. Resistance to mitogen-acti...

Introduction: Precision oncology, which aims to profile tumors for identifying actionable alterations to guide therapy has become mainstream in cancer clinics. While most approaches focus on DNA aberrancies on targeted panels, not all patients’ tumors show targetable genomic alterations in these limited gene sets, indicating a need for more compreh...

Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1. HIF‐1α inhibition in combination with anti‐angiogenic therapy is a promising anti‐tumor strategy. This Phase 1 dose‐escalation/expansi...

Purpose This first-in-human phase I dose-escalation study evaluated the safety, pharmacokinetics, and efficacy of tinengotinib (TT-00420), a multi-kinase inhibitor targeting fibroblast growth factor receptors 1-3 (FGFRs 1-3), Janus kinase 1/2, vascular endothelial growth factor receptors, and Aurora A/B, in patients with advanced solid tumors. Pat...

134 Background: Somatic BRCA1/2 mutations in BRCA-associated cancers increase therapeutic sensitivity to platinum-based chemotherapies and PARP inhibitors, but the implications of BRCA mutations in non- BRCA-associated cancers such as CRC is unknown and hypothesized to be shaped by tumor lineage. We thus conducted a retrospective analysis of outcom...

Background Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through upstream activation of 5′-AMP-activated protein kinase (AMPK) suggesting combination therapy may enhance antitumor activity of sapanisertib. We report preliminary safety, tolerability,...

294 Background: Immunotherapy (IO)-related fatigue is a common yet underrecognized adverse event (AE). The objective of this study was to determine the frequency of IO-related fatigue and non-IO-related fatigue, contributing factors, and the association between fatigue and treatment outcome in patients with advanced tumors, who received different t...

Background Immune checkpoint blockade has shown mixed results in advanced/recurrent gynecologic malignancies. Efficacy may be improved through costimulation with OX40 and 4‐1BB agonists. The authors sought to evaluate the safety and efficacy of avelumab combined with utomilumab (a 4‐1BB agonist), PF‐04518600 (an OX40 agonist), and radiotherapy in p...

There is a significant Martian ion escape channel called the “plume”. Due to the lack of multi-point, high-resolution field and particle detections, the energization mechanism and source region identification of ion plumes by in situ measurements remain unclear. China's first Mars exploration mission, Tianwen-1, provides us an opportunity to study...

Purpose Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or compensatory mechanisms. Herein, we sought to determine the feasibility and safety of neratinib and trametinib in patients with EGFR mut...

Background: Preclinical models suggest synergy between anti-angiogenesis therapy, mammalian target of rapamycin (mTOR), and histone deacetylase inhibitors to promote anticancer activity. Methods: This phase I study enrolled 47 patients between April 2012 and 2018 and determined safety, maximum tolerated dose (MTD), and dose-limiting toxicities (...

Purpose: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy. Experimental design: Copy number and genomic sequencing data from The Cancer Genome Atlas and MD Anderson Cancer Center databases were analyzed to assess ERBB2 and CCNE1 expres...

3100 Background: Colony-stimulating factor 1 (CSF-1) pathway is involved in the development of various types of cancer. Pimicotinib is an orally available, selective, potent small molecule CSF-1R inhibitor with significant pre-clinical anti-tumor activity. Here we present the results of the phase 1 trial. Methods: The escalation part employed a 3+3...

5513 Background: Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor demonstrating single-agent antitumor activity. Azenosertib may inhibit CT-induced DNA damage repair and provide benefit in pts with platinum R/R EOC. Cyclin E1 amplification/overexpression is present in ≥35% of metastatic ovarian cancer. High expressi...

e18594 Background: Ethically and scientifically clinical trials must be equally accessible. Unfortunately, racial and ethnic minorities, socioeconomically disadvantaged, elderly and rural populations continue to be underrepresented in all phases of cancer clinical trials due to multiple interrelated economic, cultural, social and medical barriers....

2525 Background: LVGN6051 is a conditional 4-1BB agonistic monoclonal antibody with Fc γ-receptor IIB selective binding in the tumor microenvironment for optimal activity. Preclinical studies showed potent antitumor activity by LVGN6051 alone and in combination with anti-PD-1 antibody. Methods: We conducted this first in human (FIH) multicenter pha...

2564 Background: The TLR-9 agonist lefitolimod (MGN1703) significantly increases the Th1 response in pre-clinical models and has demonstrated antitumor activity in early phase clinical trials. This trial assessed the safety and preliminary efficacy of the rational combination of lefitolimod with ipilimumab in patients (pts) with advanced solid tumo...

3600 Background: Sporadic young onset colorectal cancer (YOCRC, ages 30-49) is a public health crisis with a persistent rise in incidence globally. While a proportion of patients (pts) develop YOCRC due to hereditary predisposition, the majority develop sporadic microsatellite stable (MSS) colorectal cancer with limited options beyond standard of c...

12117 Background: The overall goal of our prospective and longitudinal study (NCI R01CA242565) is to examine the use of patient report to evaluate symptomatic adverse events associated with combination treatment including at least one immune checkpoint inhibitor in early-stage clinical trials. We present here the baseline symptom, health status and...

Alfven-branch waves provide an efficient means for transporting energy into the auroral oval. Here, we report observations of these waves obtained by the Fengyun-3E (FY-3E)/ACMag instruments, which are designed to detect three-dimensional AC magnetic fields in the 0.05–25 Hz band. The observations suggest that broadband waves are a permanent featur...

Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary objectives were clinical response and survival. One...

Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes...

BACKGROUND: Intra-tumoral Clostridium novyi-NT (non-toxic) is an attenuated strain of C. novyi lacking alpha toxin replication within hypoxic tumor regions, causing tumor cell lysis and inflammation. Immunotherapy (IO) augments anticancer activity with intratumoral agents in prior preclinical and clinical studies. This phase 1b dose escalation stud...

Introduction: Clinical trials are exploring ATR inhibitors (ATRi) in genomically selected contexts. However, dose-dependent anemia has limited the therapeutic index of this class. We hypothesized that monocytes and reticulocytes are more vulnerable to ATRi due to their lack of base excision repair and high levels of oxidative stress, respectively....

The Earth’s magnetospheric cusp, a region with an off-equatorial magnetic field minimum, is an important place which directly transports plasma and energy from the solar wind into the magnetosphere and ionosphere. Its magnetic topology and charged particles therein are known to respond to the solar wind and the interplanetary magnetic field. Howeve...

Plain Language Summary Previous observations of wave modulation showed that chorus waves are often excited preferentially near the magnetic field troughs of ULF waves. In this study, we report for the first time the periodic occurrence of lower‐band chorus waves near the crests of ULF wave field, although upper‐band chorus waves are still excited n...

Tides are universal and affect spatially distributed systems, ranging from planetary to galactic scales. In the Earth–Moon system, effects caused by lunar tides were reported in the Earth’s crust, oceans, neutral gas-dominated atmosphere (including the ionosphere) and near-ground geomagnetic field. However, whether a lunar tide effect exists in the...

Objective Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of selinexor and weekly paclitaxel. Methods This was an open label, single-center, multi-arm phase 1b study utilizing a...

Purpose: Preclinical cancer models harboring CCNE1 amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we conducted this phase II study to assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors. Patients and methods:...

Cyclotron resonance between plasma waves and charged particles is a fundamental and ubiquitous process in the plasma universe, during which the particle’s gyromotion has a constant phase in the wave field to enable a sustained energy exchange. In this classical picture, however, the particle’s angular velocity is determined only by the background m...

Purpose: Recently the Connective Tissue Oncology Society published consensus guidelines for recognizing Ultrarare Sarcomas (URS), defined as sarcomas with an incidence <1 per 1,000,000. We assessed the outcomes of 56 patients with soft tissue, and 21 with bone sarcomas, enrolled in phase 1 trials. Experimental design: In this SArcoma Matched Bio...

Introduction/Background Few treatment options exist in recurrent cervical cancer, which makes phase 1 clinical trials a compelling option. In order to identify candidates for referral, we analyzed factors predictive of response and survival in cervical cancer patients referred to phase 1 trials. Methodology Cervical cancer patients who received at...

We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms when eligibility criteria were met (Part A). In Part B, patients who declined ra...

A single satellite hardly measures the overall ion escape rate from a planet. Therefore, the question concerning the long-term atmospheric evolution of whether a planetary magnetic field protects its atmosphere or aggravates atmospheric loss remains unresolved. Here, combined data from multiple platforms including Cluster, DMSP, IMAGE, and Polar sa...

Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We performed a prospective longitudinal study to capture patient-r...

Plain Language Summary In the dusk to midnight plasma sheet, the fluxes of counter‐streaming energetic electrons were often observed to fluctuate at the period about 2 ∼ 6 min, with the higher energy fluxes coming to peaks earlier than those at lower energies. These phenomena were considered to be caused by repetitive injections of electrons with s...

PURPOSE The response to cancer therapies is typically assessed with radiologic imaging 6-10 weeks after treatment initiation. Circulating tumor DNA (ctDNA), however, has a short half-life, and dynamic changes in ctDNA quantity may allow for earlier assessment of the therapeutic response. METHODS Patients with advanced solid tumors referred to the...

Plain Language Summary In Earth's Van Allen radiation belts, energetic particles are magnetically trapped to form a hazardous environment for spacecraft and astronauts. These particles can stay trapped for years before they are scattered toward the atmosphere by resonant interactions with plasma waves. Among these waves, the electromagnetic ion cyc...

BACKGROUND: BRAF V600 mutations are driver oncogenes in multiple human cancers. Given complex resistance mechanisms beyond combined MEK inhibition, limited data exists to evaluate combinations with CRAF/ARAF/MET/mTOR inhibitors and cytotoxic chemotherapy in sustaining response and overcoming resistance. We explore patient outcomes comparing vemuraf...

Energetic electron measurement is of great significance to theoretical space physics research and space weather applications. Current energetic electron detectors must cooperate with a spin-stabilized satellite platform to achieve high angular resolution in pitch angle distribution and three-dimensional imaging measurement of energetic electrons. T...

3076 Background: The implementation of genomic profiling with next generation sequencing has revolutionized the field of precision oncology. Comprehensive genomic testing of tumors to identify actionable genomic alterations is now commonly performed in the care of patients with advanced/metastatic disease. Although the genomic profile of tumors has...

1588 Background: Emerging clinical studies report correlation of time-of-day infusion (TOI) to immunotherapy outcomes and the intricate interplay of the human circadian rhythm and cancer and immunotherapy exposure. Preclinical and clinical studies have shown cancer chronotherapy to play important role in transcriptional rhythmicity of oncogenic pro...

Immune checkpoint inhibitor anemias (ICI-A) are a rare entity which can be potentially life-threatening without prompt identification. The goal of the study is to characterize the presentation, evaluation, and outcomes of ICI therapy in early phase clinical trial setting to guide future research and to develop standardized care guidelines. Retrospe...

4551 Background: SEL is a first-in-class nuclear exportin 1 inhibitor, which blocks the transport of several proteins involved in cancer-cell growth from the nucleus to the cytoplasm. A syngeneic RENCA mouse model showed that SEL combined with checkpoint blockade resulted in increased effector and activated T cells, and NKT cells and reductions in...

3013 Background: TT-00420 is a spectrum-selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology pathways by inhibiting Aurora kinases A/B and Janus kinases (JAK) involved in cytokine signaling and receptor tyrosine kinases (FGFRs and VEGFRs) involved in the tumor microenvironment. TT-00420 has demonstrate...

3111 Background: Ongoing trials are exploring ATR inhibitors (ATRi) in genomically selected contexts. However, myelosuppression, particularly anemia, has limited the therapeutic window of this class of drugs. We sought to discover clinical biomarkers predicting severe hematological toxicity from ATRi. Methods: We retrospectively analyzed clinical p...

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 ampl...

Plain Language Summary In Earth's magnetosphere, plasma waves play a key role in the acceleration, transport, and loss of energetic particles in the Van Allen radiation belts. These waves usually coexist and interact with one another. For example, whistler waves in the kHz range are often modulated by ultralow frequency (ULF) waves in the mHz range...

Drift‐bounce resonance between ultralow frequency (ULF) waves and ions is essential for ion energization in the magnetosphere. Here, we present the first comprehensive study of drift‐bounce resonance in the dayside outer magnetosphere, where off‐equatorial magnetic field minima would strongly distort ions' bounce and drift motion. A generalized the...

At Mercury, several processes can release ions and neutrals out of the planet's surface. Here we present enhancements of planetary ions (Na⁺‐group ions) in Mercury's northern magnetospheric cusp during flux transfer event (FTE) “showers.” FTE showers are intervals of intense dayside magnetopause reconnection, during which FTEs are observed in quick...